-
DITAS: Discovery of autoantigens that cause immunotherapy side effects (irAEs
Time of Update: 2022-09-15
The article was published in a new issue of Science ImmunologyBased on a single-sample gene set enrichment analysis, the authors calculated the similarity of transcripts between lung tumors and healthy lung tissue with DITAS, from which 10 lung tissue-specific genes were highly expressed in lung tumors, and then performed immune peptide analysis to determine which HLA these peptides bind to, predicted the T cell epitopes of CD8+ these peptides, and performed functional verification to identify candidate antigens.
-
Music marketing has become the focus of brand breakthrough
Time of Update: 2022-09-01
(Wang Wen) "China Food News" (August 23, 2022 08 edition) (Editor-in-charge: Gao Na) As one of the entertainment marketing methods, music marketing can break through the sensory limitations of visual contact and affect the emotions of the human brain through the subconscious, which is more likely to cause widespread emotional waves, triggering out-of-the-circle communication and many other advantages.
-
Express significantly improves the symptoms of Parkinson's disease patients, and the phase 2 clinical results of the new mechanism therapy are positive
Time of Update: 2022-04-27
▎WuXi AppTec Content Team Editors Today, Cerevance announced that its potential "first-in-class" oral Parkinson's disease treatment CVN424 has achieved positive results in a Phase 2 clinical trial .
" Reference: [1] Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism.
-
J Clin Endocrinol Metab: Zoledronic acid versus placebo in pediatric glucocorticoid-induced osteoporosis
Time of Update: 2022-01-22
prevention A retrospective observational study of IVZA in children with GC-treated disease and fragility fractures showed increases in bone mineral density parameters and no new VF .
-
The first in China
Time of Update: 2022-01-01
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, the official website of CDE showed that the clinical trial application for IPG1094 tablets of Aimefel Biosciences has been approved by the China Food and Drug Administration for the treatment of solid tumors and multiple myeloma .
-
More than 600 million U.S. dollars to help develop a new AAV gene therapy Pfizer reached a partnership
Time of Update: 2021-10-22
Use Voyager's new adeno-associated virus (AAV) capsid development platform to help Pfizer develop two gene therapies to treat neurological and cardiovascular diseases .
Reference materials:[1] Voyager Therapeutics Announces License Option Agreement With Pfizer For Next-Generation TRACERᵀᴹ AAV Capsids To Enable Neurologic And Cardiovascular Gene Therapy Programs.
-
Cell Rep: Early exposure to antibiotics affects health and longevity in later life
Time of Update: 2021-09-10
In addition, it is difficult to determine whether any association between the gut microbiota and longevity is mainly due to early life effects or due to changes in the composition and diversity of the gut microbiota during aging .
The composition of the gut microbiota following early-life antibiotic exposure affects host health and longevity in later life .
-
How can nanoparticles help cancer research
Time of Update: 2020-07-31
Doi: 10.1038/s41563-019-0566-2 Researchers from the University of Toronto found that it was an active, rather than passive, process that determines which nanoparticles enter solid tumors, a finding that upends previous ideas in the field of cancer nanomedicine and points the way for more effective nanotherapy, the findings of which were published recently in the journal Nature Materials.
-
What are monoamine oxidase inhibitors
Time of Update: 2020-04-03
Monoamine oxidase inhibitors (MAOIs) are a kind of antidepressants They are often used to treat atypical depression and quit smoking Because of strict dietary restrictions, this kind of antidepressant
-
J Med Chem: HIV drug feveron may be expected to treat Alzheimer's disease
Time of Update: 2020-01-07
January 7, 2020 / BIOON / -- recently, an International Journal of medical chemistry In the previous research report, scientists from Vanderbilt University and other institutions found that a drug use
-
Recovery of immune system balance: ROCK2 inhibitor reaches the key clinical end point
Time of Update: 2019-11-13
Today, kadmon announced that its in-depth oral selective Rock2 inhibitor kd025 for the treatment of chronic graft-versus-host disease (cGVHD) reached the primary end point of overall response rate (OR
-
Intravesical chemotherapy + systemic immunotherapy! Tar-200 / opdivo in the treatment of stage IB muscle invasive bladder cancer
Time of Update: 2019-07-15
July 15, 2019 / Bio Valley bio / - Taris bio is a biopharmaceutical company dedicated to the development of transformative therapies for the treatment of urinary system diseases causing failure Recent
-
HISCO's first copy was approved, with sales of $69 million
Time of Update: 2018-12-21
On December 20, 2018, hisic Pharmaceutical Group Co., Ltd announced that its wholly-owned subsidiary Sichuan hisic Pharmaceutical Co., Ltd had recently received the approval document for drug registra
-
The first new Chinese medicine "Xiaoer Huanglong granule (Jingning)" for the treatment of ADHD in China is on the market
Time of Update: 2015-05-29
According to Chongqing Science and Technology Commission, the new traditional Chinese medicine "Xiaoer Huanglong granule (jingyining ®)" independently developed by Chongqing hilan Pharmaceutical Co.,
-
Novartis Japan was ordered to shut down for half a month for concealing side effects
Time of Update: 2015-03-02
Source: Biovalley March 2, 2015 Japanese health authorities ordered Novartis Japan branch to close most of its operating plants for 15 days in March, because Novartis did not disclose the side effects
